+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5006322
  • Report
  • April 2020
  • Region: Global
  • 237 Pages
  • DelveInsight

FEATURED COMPANIES

  • Allergan
  • Dompé Farmaceutici
  • Horama
  • jCyte
  • MeiraGTx
  • Neurotech
‘Retinitis Pigmentosa (RP) - Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Retinitis Pigmentosa (RP) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Retinitis Pigmentosa (RP) - Disease Understanding and Treatment Algorithm

Retinitis Pigmentosa (RP) - Overview

Retinitis Pigmentosa (RP) refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Individuals with RP lose their vision because of the gradual degeneration of photoreceptor (light-sensing) cells of the retina. In most forms of RP (rod-cone dystrophy), night blindness is one of the earliest and most frequent symptoms. Based on clinical impact, RP is classified into three categories that include, non-syndromic, or "simple" (not affecting other organs or tissues), Syndromic (affecting other neurosensory systems such as hearing), and Systemic (affecting multiple tissues. Non-syndromic RP has three-stage: early stage, mid and end-stage. Non-syndromic RP is further subcategorized as autosomal dominant RP, autosomal recessive RP, X-linked RP, sporadic/simplex RP, and Leber congenital amaurosis (LCA).

Syndromic and Systemic RP are subcategorized into usher syndrome, bardet-biedl syndrome, and others.

Retinitis Pigmentosa (RP) Diagnosis

The diagnosis of RP is suspected in patients with poor night vision or family history (more than 40% of RP cases in the US have no family history). It relies upon documentation of rod dysfunction as measured by dark adaptation or electroretinogram, progressive loss in photoreceptor function, loss of peripheral vision and bilateral involvement.

The most common findings on ocular examination are usually preserved visual acuity until late-stage disease and reduced visual fields. Most adult patients have posterior subcapsular cataracts and visual acuity that varies from 20/20 to near blindness late in the disease.

Retinitis Pigmentosa (RP) Treatment

It covers the details of conventional and current medical therapies available in the Retinitis Pigmentosa (RP) market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the 7MM.

The Retinitis Pigmentosa (RP) market report gives a thorough understanding of Retinitis Pigmentosa (RP) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Retinitis Pigmentosa (RP) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Cases of Retinitis Pigmentosa in the 7MM, Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM, Subtype-Specific Diagnosed Prevalence of Syndromic and Systemic RP in the 7MM, and Subtype-specific Diagnosed Prevalent Cases of Non-Syndromic RP in the 7MM) scenario of Retinitis Pigmentosa in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

Key Findings

This section provides glimpses of the Retinitis Pigmentosa epidemiology in the 7MM market.

According to the publisher's, the total diagnosed prevalent population of Retinitis Pigmentosa (RP) in the 7MM was 253,420 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Country Wise-Retinitis Pigmentosa Epidemiology

The epidemiology segment also provides the Retinitis Pigmentosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Retinitis Pigmentosa Drug Chapters

The drug chapter segment of the Retinitis Pigmentosa report encloses the detailed analysis of Retinitis Pigmentosa marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the RP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Retinitis Pigmentosa Marketed Drugs

Luxturna: Spark Therapeutics/ Novartis

Luxturna (AAV2-hRPE65v2; voretigene neparvovec), known as voretigene neparvovec-rzyl, is a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. It provides a copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells.

The drug was developed and commercialized in the US by Spark Therapeutics. In Europe, Novartis is currently marketing Luxturna as per a licensing agreement covering the development, registration and commercialization rights of Luxturna in markets outside the US. It is indicated for the treatment of patients with vision loss due to Leber's congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.

Product details in the report.

Retinitis Pigmentosa Emerging Drugs

HORA-RPE65: Horama

Horama is developing a HORA-RPE65 gene replacement product for the treatment of RPE65 Retinitis Pigmentosa. It is an AAV 2/4 encapsidating the human RPE65 gene under the control of the human native RPE65 promoter. The company investigational candidate HORA-RPE65 provides the cell with a non-mutated copy of the human RPE65 gene, which can express functional RPE65 protein to halt or at least significantly delay retinal degeneration in patients with inherited retinal dystrophies caused by RPE65 gene mutations.

The drug is being delivered in the form of a sterile vector suspension injected directly into the subretinal space, where it induces transgene expression in retinal pigment epithelium cells. Horama had already completed a single-center, open, non-randomized phase I/II clinical trial which accessed the safety and effectiveness of HORA-RPE65 in patients with retinal dystrophy caused by RPE65 gene abnormalities.

Product details in the report.

Retinitis Pigmentosa Market Outlook

The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Retinitis Pigmentosa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Retinitis Pigmentosa 7MM market. The market size of Retinitis Pigmentosa in the 7MM market was USD 237.27 million in 2017.

The United States Market Outlook

This section provides the total Retinitis Pigmentosa market size and market size by therapies in the United States.

Among the 7MM countries, the United States had the highest market size of RP in 2017, which accounts for 56.40% of the total market. At present, the growth of market size for RP is attributed to support treatment regimens, the only approved therapy (Luxturna), as well as, emerging therapies. The market size for RP was found to be USD 133.82 million in 2017.

EU-5 Market Outlook

The total Retinitis Pigmentosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Germany accounts for 26.28% of the total EU-5 market of RP. The publisher's estimates suggest that the overall market size of RP was observed to remain nearly constant from USD 20.90 million in 2017 to USD 21.33 million in 2018. This is attributed to the dependency of the market size of RP on supportive treatment regimens, at present. However, with the recent approval of Luxturna, the market size of RP is expected to experience a significant increase. The dearth of marketed treatment regimens for RP is the foremost unmet need of this therapeutic area, which is primarily responsible for nearly constant market size.

Japan Market Outlook

The total Retinitis Pigmentosa market size and market size by therapies in Japan are provided.

Retinitis Pigmentosa Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Retinitis Pigmentosa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Retinitis Pigmentosa market uptake by drugs; patient uptake by therapies; and sales of each drug.

Retinitis Pigmentosa Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Retinitis Pigmentosa emerging therapies.

Reimbursement Scenario in Retinitis Pigmentosa

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in Retinitis Pigmentosa domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Retinitis Pigmentosa market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Retinitis Pigmentosa market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Retinitis Pigmentosa, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Retinitis Pigmentosa epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Retinitis Pigmentosa are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Retinitis Pigmentosa market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Retinitis Pigmentosa market
Report Highlights
  • In the coming years, Retinitis Pigmentosa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Retinitis Pigmentosa. Launch of emerging therapies will significantly impact the Retinitis Pigmentosa market
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Retinitis Pigmentosa Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Retinitis Pigmentosa Pipeline Analysis
  • Retinitis Pigmentosa Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Retinitis Pigmentosa Report Key Strengths
  • Eleven Years Forecast
  • 7MM Coverage
  • Retinitis Pigmentosa Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Retinitis Pigmentosa Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the Retinitis Pigmentosa market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Retinitis Pigmentosa total market size as well as market size by therapies across the globe during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the globe and which country will have the largest Retinitis Pigmentosa market size during the forecast period (2020-2030)?
  • At what CAGR, the Retinitis Pigmentosa market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Retinitis Pigmentosa market outlook across the globe during the forecast period (2020-2030)?
  • What would be the Retinitis Pigmentosa market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of Retinitis Pigmentosa?
  • What is the historical Retinitis Pigmentosa patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Retinitis Pigmentosa at the 7MM level?
  • What will be the growth opportunities across the globe with respect to the patient population pertaining to Retinitis Pigmentosa?
  • Out of the above-mentioned countries, which country would have the highest Incident population of Retinitis Pigmentosa during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the globe during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Retinitis Pigmentosa along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Retinitis Pigmentosa in the 7MM?
  • What are the Retinitis Pigmentosa marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Retinitis Pigmentosa?
  • How many therapies are developed by each company for the treatment of Retinitis Pigmentosa?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Retinitis Pigmentosa?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Retinitis Pigmentosa and their status?
  • What are the key designations that have been granted for the emerging therapies for Retinitis Pigmentosa?
  • What are the 7MM historical and forecasted market of Retinitis Pigmentosa?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Retinitis Pigmentosa.
  • To understand the future market competition in the Retinitis Pigmentosa market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Retinitis Pigmentosa in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Retinitis Pigmentosa market.
  • To understand the future market competition in the Retinitis Pigmentosa market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan
  • Dompé Farmaceutici
  • Horama
  • jCyte
  • MeiraGTx
  • Neurotech
1. Key Insights

2. Executive Summary of Retinitis Pigmentosa (RP)

3. Retinitis Pigmentosa (RP): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of RP in 2017
3.2. Total Market Share (%) Distribution of RP in 2030

4. Retinitis Pigmentosa: Disease Background and Overview
4.1. Introduction
4.2. History
4.3. Facts about Retina
4.4. Signs and Symptoms
4.5. Causes of Retinitis Pigmentosa
4.6. Clinical Features
4.7. Classification of Retinitis Pigmentosa
4.7.1. Classification as per Japanese guidelines
4.8. Pathophysiology
4.9. Etiology
4.10. Genetics of Retinitis Pigmentosa
4.10.1. Types of non-syndromic RP inheritance
4.11. Diagnosis
4.11.1. Recommended Diagnostic Tests
4.11.2. Differential diagnosis of RP

5. Case Reports
5.1. A Case of Unilateral Retinitis Pigmentosa Associated with Full-Thickness Macular Hole
5.2. Eleven-Year Follow-Up of a Japanese Retinitis Pigmentosa Patient with an HK1 Gene Mutation
5.3. Unilateral Retinitis Pigmentosa: Visual field changes in a 31-year-old female

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM
6.4. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
6.5. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM
6.6. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic Retinitis Pigmentosa in the 7MM
6.7. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United States
7.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
7.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States
7.5. Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic RP in the United States
7.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany
8.1.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
8.1.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany
8.1.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany
8.1.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France
8.2.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
8.2.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France
8.2.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France
8.2.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy
8.3.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
8.3.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy
8.3.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy
8.3.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain
8.4.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
8.4.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain
8.4.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain
8.4.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom
8.5.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
8.5.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom
8.5.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the United Kingdom
8.5.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan
9.3. Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
9.4. Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan
9.5. Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan
9.6. Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices
10.1. General recommendations for RP treatment
10.2. Current Treatment Modalities
10.3. Future Treatment modalities

11. Proposed Guidelines for Retinitis Pigmentosa

12. Unmet Needs

13. Marketed Products
13.1. Luxturna: Spark Therapeutics/ Novartis
13.1.1. Drug Description
13.1.2. Regulatory Milestones
13.1.3. Product Development Activities
13.1.4. Advantages and Disadvantages
13.1.5. Safety and Efficacy
13.1.6. Product Profile

14. Emerging Therapies
14.1. Key Cross Competition
14.2. HORA-RPE65: Horama
14.2.1. Product Description
14.2.2. Other development Activities
14.2.3. Product Profile
14.3. HORA-PDE6B: Horama
14.3.1. Product Description
14.3.2. Other development Activities
14.3.3. Clinical Development
14.3.4. Product Profile
14.4. AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen
14.4.1. Product Description
14.4.2. Other development Activities
14.4.3. Clinical Development
14.4.4. Safety and Efficacy
14.4.5. Product Profile
14.5. jCell: jCyte
14.5.1. Product Description
14.5.2. Other development Activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.5.5. Product Profile
14.6. Renexus: Neurotech
14.6.1. Product Description
14.6.2. Other Development Activities
14.6.3. Clinical Development
14.6.4. Product Profile
14.7. Cenegermin: Dompé Farmaceutici
14.7.1. Product Description
14.7.2. Other development Activities
14.7.3. Clinical Development
14.7.4. Safety and Efficacy
14.7.5. Product Profile
14.8. hRPC Cells : ReNeuron
14.8.1. Product Description
14.8.2. Other development Activities
14.8.3. Clinical Development
14.8.4. Safety and Efficacy
14.8.5. Product Profile
14.9. UshStat: Sanofi (Terminated)
14.9.1. Product Description
14.9.2. Other development Activities
14.9.3. Clinical Development
14.9.4. Safety and Efficacy
14.9.5. Product Profile
14.10. AGN-151597: Allergan
14.10.1. Product Description
14.10.2. Other development Activities
14.10.3. Clinical Development
14.10.4. Product Profile
14.11. AAV-RPGR: MeiraGTx
14.11.1. Product Description
14.11.2. Other development Activities
14.11.3. Clinical Development
14.11.4. Product Profile
14.12. AAV-RPE65: MeiraGTx
14.12.1. Product Description
14.12.2. Other development Activities
14.12.3. Clinical Development
14.12.4. Safety and Efficacy
14.12.5. Product Profile

15. Retinitis Pigmentosa (RP): 7MM Market Analysis
15.1. Key Findings
15.2. Market Estimation Methodology
15.3. Attribute Analysis
15.4. Market Size of Retinitis Pigmentosa in the 7MM
15.5. Market Size of Retinitis Pigmentosa by Therapies in the 7MM
15.6. Retinitis Pigmentosa: Emerging Market Competition

16. United States: Market Outlook
16.1. United States Market Size
16.1.1. Total Market size of Retinitis Pigmentosa in the United States
16.1.2. Market Size of Retinitis Pigmentosa by Therapies in the US

17. EU-5 countries: Market Outlook
17.1. Germany Market Size
17.1.1. Total Market size of Retinitis Pigmentosa in Germany
17.1.2. Market Size of Retinitis Pigmentosa by therapies in Germany
17.2. France Market Size
17.2.1. Total Market size of Retinitis Pigmentosa in France
17.2.2. Market Size of Retinitis Pigmentosa by therapies in France
17.3. Italy Market Size
17.3.1. Total Market size of Retinitis Pigmentosa in Italy
17.3.2. Market Size of Retinitis Pigmentosa by therapies in Italy
17.4. Spain Market Size
17.4.1. Total Market size of Retinitis Pigmentosa in Spain
17.4.2. Market Size of Retinitis Pigmentosa by therapies in Spain
17.5. United Kingdom Market Size
17.5.1. Total Market size of Retinitis Pigmentosa in the United Kingdom
17.5.2. Market Size of Retinitis Pigmentosa by therapies in the UK

18. Japan Market Outlook
18.1. Japan Market Size
18.1.1. Total Market size of Retinitis Pigmentosa in Japan
18.1.2. Market Size of Retinitis Pigmentosa by therapies in Japan

19. Access and Reimbursement Overview of Retinitis Pigmentosa
19.1. Current therapy-Luxturna
19.2. Outline of the Patient Journey with Luxturna Introduced by Spark Therapeutics
19.3. Coverage Parameters for Luxturna
19.4. Payer billing guidelines for claims processing and prompt payment of Luxturna
19.5. Future Potential Therapies

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Appendix
23.1. Report Methodology

24. Capabilities

25. Disclaimer

26. About the Publisher
Note: Product cover images may vary from those shown
  • Horama
  • Nightstar Therapeutics/Biogen
  • jCyte
  • Neurotech
  • Dompé Farmaceutici
  • ReNeuron
  • Sanofi (Terminated)
  • Allergan
  • MeiraGTx
Note: Product cover images may vary from those shown
Adroll
adroll